5-HT receptor ligands and uses thereof

A compound of Formula (IC)

• wherein
• X and Y are CR and Z is N, or X is N and Y and Z are CR, where R for each occurrence is hydrogen, halogen, (C1-C4)alkyl, amino, or (C1-C4)alkylamino;
• W is oxy, thio, amino, (C1-C4)alkylamino, or acetylamino;
• Q is a heteroaryl group selected from the group consisting of pyridin-2-yl, pyridin-3-yl, furan-3-yl, furan-2-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, pyrrol-2-yl, pyrrol-3-yl, pyrazol-3-yl, quinolin-2-yl, quinolin-3-yl, isoquinolin-3-yl, benzofuran-2-yl, benzofuran-3-yl, isobenzofuran-3-yl, benzothiophen-2-yl, benzothiophen-3-yl, indol-2-yl, indol-3-yl, 2H-imidazol-2-yl, oxazol-2-yl, isoxazol-3-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-triazol-3-yl, and 1,2,4-oxathiazol-3-yl, where said heteroaryl group is optionally substituted with one to three substituents independently selected from halo, (C1-C4)alkyl or (C1-C4)alkyoxy;
• R2a and R2b are each independently hydrogen, (C1-C4)alkyl, or partially or fully saturated (C3-C6)cycloalkyl;
• R3a and R3b are each independently hydrogen, (C1-C4)alkyl, or (C1-C4)alkyl substituted with hydroxy, fluoro, or (C1-C4)alkoxy;
• R4 is hydrogen, hydroxy, (C1-C4)alkyl, (C1-C4)alkyl substituted with hydroxy or cyano, (C1-C4)alkylcarbonyl, (C1-C4)alkoxy, (C1-C4)alkoxy-carbonyl, or (C3-C4)alkenyl;
• a nitrogen oxide thereof, a prodrug of said compound or said nitrogen oxide;
• a pharmaceutically acceptable salt of said compound, said nitrogen oxide, or said prodrug, or a solvate or hydrate of said compound, said nitrogen oxide, said prodrug, or said salt.